In the United States, deaths due to opioid overdose (prescription opioid and heroin) have increased 200% since 2000, approximating death rates due to pneumonia and influenza. Deaths due to sedative-hypnotic overdose have quadrupled since 1996. Suicides increased approximately 30% since 2000—not accounting for substance-related poisonings having a component of intentional self-harm but coded as unintentional or undetermined cause due to absence of a suicide note and other corroborative evidence. Emerging national data suggest significant suicidality associated with substance and prescription overdose, indicating that clinicians are missing critical opportunities for prevention of premature mortality. This webinar will review the proposed death sub-category, “death from drug self-intoxication,” as a surveillance strategy for improving accurate detection of a preventable death. Clinical translations of this concept, including empirical opportunities to elicit self-harm/suicide risk and to intervene with patients and families seeking treatment in a variety of clinical practice settings, will be presented.
Funding for this initiative was made possible (in part) by grant no. 5U79TI026556-03 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. pcssnow.org
- General Member - Free
- Resident-Fellow Member - Free
- Medical Student Member - Free
- Non-Member - Free
- Cite international and national vital statistics data demonstrating more than a decade of pandemic drug overdose deaths, and discuss the associated problem of undercounting suicides in cases involving substance misuse.
- Describe self-harm and suicide risk cognitions commonly encountered in substance use disorder patients presenting to treatment.
- Explain the need to assess self-harm/suicide risk independently of routine mental health assessments for mood disorders, PTSD, psychotic disorders, and personality disorders.
Physicians and other clinicians with interests in safe and effective use of opioid medications for the treatment of chronic pain and the interface of pain and opioid use disorder.
Estimated Time to Complete
Estimated Duration: 1 Hour
Start Date: June 21, 2016
Review Date: June 21, 2019
End Date: June 21, 2020
How to Earn Credit
Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. A multiple choice quiz is provided based on the content. A passing score of 60% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the event date and hours earned.
Continuing Education Credit
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The APA designates this enduring CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Planner Disclosures
- Ian Rockett, PhD, MPH, Professor, Department of Epidemiology, School of Public Health, West Virginia University. Reports no financial relationships with commercial interests
- Hilary Connery, M.D., PhD, Clinical Director, Division of Alcohol and Drug Abuse, McLean Hospital. Reports no financial relationships with commercial interests
- Beatrice Eld, Deputy Director of Educaton for Addiction Psychiatry, American Psychiatric Association. Reports no financial relationships with commercial interests
- John A. Renner, Jr., M.D.– Boston University School of Medicine, Director, Addiction Psychiatry Residency Training, Boston University Medical Center and VA Boston Healthcare System. Disclosure: Stock/other financial options: Johnson & Johnson and General Electric.
Program Reviewers (June 21, 2019)
- John A. Renner, Jr., M.D., Boston University School of Medicine, Director, Addiction Psychiatry Residency Training, Boston University Medical Center and VA Boston Healthcare System. Disclosure: Stock/other financial options: Johnson & Johnson and General Electric.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.
Optimal System Configuration:
- Flash Player: Adobe Flash Player 10.3+
- Browser: Firefox (latest version), Internet Explorer 8.0+, Safari 7.0+, Microsoft Edge (latest version) or Google Chrome (latest version)
- Operating System: Windows XP+ or Mac OS X 10.4+
- Internet Connection: 1 Mbps or higher
- Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Macromedia Flash Player 10.3 or higher; Sound Card at least 16-bit; audio playback with speakers for programs with video content
- Macintosh:Mac OS X 10.4+ or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit; audio playback with speakers for programs with video content
For assistance: Contact email@example.com questions about this course | Contact firstname.lastname@example.org for technical assistance